Security key
88427A107
THIRD HARMONIC BIO, INC. - Common Stock, par value $0.0001 per share (THRD)
CUSIP: 88427A107
Q3 2023 13F Holders as of 30 Sep 2023
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Total 13F shares
- 37,791,218
- Total 13F value
- $241,485,993
- Share change
- +1,730,428
- SEC-reported price per share
- $6.39
- Number of holders
- 54
- Value change
- +$16,508,379
- Number of buys
- 30
- Number of sells
- 14
- Shares outstanding
- 45,416,671
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2023
Institutions
54
Top holders
10
THRD full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Third Harmonic Bio, Inc. SEC filings
Third Harmonic Bio, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 88427A107
Recent filing periods:
Ownership snapshot
Top reported holders of THRD - THIRD HARMONIC BIO, INC. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Atlas Venture Life Scienc...
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
30 Jun 2023
13F
3/4/5
Lead comparable stake: 24%
Showing 1-6 of 15 holder rows.
Quick read
Atlas Venture Life Science Advisors, LLC leads the comparable SEC ownership view at 24%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Atlas Venture Life Science Advisors, LLC's linked filing trail.
Comparable ownership
Top 5
Atlas Venture Life Science Adviso...
24%
ORBIMED ADVISORS LLC
13%
BVF INC/IL
9.6%
GENERAL ATLANTIC, L.P.
6.5%
Stonepine Capital Management, LLC
6.2%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC |
13F
Company
|
24%
|
$52,466,802
10,907,859 shares
|
— | 30 Jun 2023 |
| ORBIMED ADVISORS LLC |
3/4/5
13F
Director, 10%+ Owner · Company
|
13%
from 13F
|
$59,522,120
5,779,071 shares
|
— | 19 Sep 2022 |
| BVF INC/IL |
13F
Company
|
9.6%
|
$21,000,138
4,365,933 shares
|
— | 30 Jun 2023 |
| GENERAL ATLANTIC, L.P. |
13F
Company
|
6.5%
|
$14,231,645
2,958,762 shares
|
— | 30 Jun 2023 |
| Stonepine Capital Management, LLC |
13F
Company
|
6.2%
|
$13,435,047
2,793,149 shares
|
— | 30 Jun 2023 |
| EcoR1 Capital, LLC |
13F
Company
|
4.6%
|
$10,047,032
2,088,780 shares
|
— | 30 Jun 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
54
Shares
37,791,218
Rows available
54
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2023 vs Q1 2026 Across Filers
Q1 2026 holders
3
Q3 2023 holders
54
Holder diff
51
| Investor | Q1 2026 Shares | Q3 2023 Shares | Share Diff | Share Chg % | Q1 2026 value | Q3 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend